B细胞-话题@MedSci

#B细胞#

314篇内容 | 4658人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273439, encodeId=ee2812e3439ea, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, objectType=article, longId=732664, objectId=82c1e326649a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1e326649a, replyNumber=0, likeNumber=136, createdTime=2022-07-19, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1e326649a, moduleTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c1e326649a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273440, encodeId=50fd12e344061, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JNNP:幼稚B细胞和水通道蛋白-4抗体是视神经脊髓炎发病的特征,来自干细胞移植的证据, objectType=article, longId=732466, objectId=6f8de32466f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f8de32466f0, replyNumber=0, likeNumber=123, createdTime=2022-07-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f8de32466f0, moduleTitle=JNNP:幼稚B细胞和水通道蛋白-4抗体是视神经脊髓炎发病的特征,来自干细胞移植的证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f8de32466f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273438, encodeId=d13c12e343833, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, objectType=article, longId=730251, objectId=bec7e302514e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec7e302514e, replyNumber=0, likeNumber=131, createdTime=2022-06-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec7e302514e, moduleTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec7e302514e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273436, encodeId=401e12e34365c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤, objectType=article, longId=730182, objectId=b81ce30182de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b81ce30182de, replyNumber=0, likeNumber=85, createdTime=2022-06-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b81ce30182de, moduleTitle=Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b81ce30182de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273437, encodeId=65ba12e343704, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nature重磅：AAV递送CRISPR，体内改造B细胞，产生广泛中和抗体治疗艾滋病, objectType=article, longId=730169, objectId=9d23e3016970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d23e3016970, replyNumber=0, likeNumber=107, createdTime=2022-06-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d23e3016970, moduleTitle=Nature重磅：AAV递送CRISPR，体内改造B细胞，产生广泛中和抗体治疗艾滋病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d23e3016970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273435, encodeId=34fd12e3435f0, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应, objectType=article, longId=729080, objectId=64cee29080f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64cee29080f1, replyNumber=0, likeNumber=92, createdTime=2022-06-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64cee29080f1, moduleTitle=A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64cee29080f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273434, encodeId=25b012e343424, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应, objectType=article, longId=729002, objectId=a298e29002b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a298e29002b7, replyNumber=0, likeNumber=95, createdTime=2022-06-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a298e29002b7, moduleTitle=A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a298e29002b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273433, encodeId=6b1f12e34331a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, objectType=article, longId=728566, objectId=eb89e28566e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e28566e7, replyNumber=0, likeNumber=95, createdTime=2022-06-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e28566e7, moduleTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e28566e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273432, encodeId=80fe12e34323c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, objectType=article, longId=726862, objectId=923fe2686288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=923fe2686288, replyNumber=0, likeNumber=89, createdTime=2022-05-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=923fe2686288, moduleTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=923fe2686288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273431, encodeId=885412e3431e4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关, objectType=article, longId=726488, objectId=0d32e2648830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d32e2648830, replyNumber=0, likeNumber=108, createdTime=2022-05-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d32e2648830, moduleTitle=A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d32e2648830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273430, encodeId=612e12e343082, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR, objectType=article, longId=725533, objectId=55e3e255332a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55e3e255332a, replyNumber=0, likeNumber=82, createdTime=2022-04-28, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55e3e255332a, moduleTitle=通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55e3e255332a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273429, encodeId=d5ec12e34291a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批, objectType=article, longId=724745, objectId=639fe24745ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=639fe24745ff, replyNumber=0, likeNumber=42, createdTime=2022-04-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=639fe24745ff, moduleTitle=药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=639fe24745ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273428, encodeId=765712e3428b9, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JCI：北大人民医院申占龙团队揭示亚洲人特异性的IgG1记忆性B细胞抗原受体变异体对结直肠癌微环境中的作用机制, objectType=article, longId=723842, objectId=7473e23842f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7473e23842f1, replyNumber=0, likeNumber=68, createdTime=2022-04-10, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7473e23842f1, moduleTitle=JCI：北大人民医院申占龙团队揭示亚洲人特异性的IgG1记忆性B细胞抗原受体变异体对结直肠癌微环境中的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7473e23842f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273427, encodeId=434312e34270c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, objectType=article, longId=301786, objectId=fb92301e86b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb92301e86b3, replyNumber=0, likeNumber=73, createdTime=2022-03-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb92301e86b3, moduleTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb92301e86b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273426, encodeId=3a9712e3426a5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗, objectType=article, longId=301401, objectId=a420301401e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a420301401e0, replyNumber=0, likeNumber=69, createdTime=2022-03-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a420301401e0, moduleTitle=Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a420301401e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273425, encodeId=e3b012e34259e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, objectType=article, longId=298992, objectId=90c929899271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c929899271, replyNumber=0, likeNumber=109, createdTime=2022-02-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c929899271, moduleTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c929899271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273424, encodeId=12d312e342459, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, objectType=article, longId=298991, objectId=961f298991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961f298991d8, replyNumber=0, likeNumber=72, createdTime=2022-02-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961f298991d8, moduleTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961f298991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273423, encodeId=8ab612e342367, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, objectType=article, longId=295542, objectId=e92329554273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92329554273, replyNumber=0, likeNumber=88, createdTime=2022-02-14, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92329554273, moduleTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92329554273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273422, encodeId=a5d712e3422d1, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=A&R：PD-1highCXCR5-CD4+外周T辅助细胞克隆扩增对抗核抗体阳性幼年特发性关节炎患者关节B细胞分化的影响, objectType=article, longId=294609, objectId=1bba29460969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bba29460969, replyNumber=0, likeNumber=75, createdTime=2022-01-25, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bba29460969, moduleTitle=A&R：PD-1highCXCR5-CD4+外周T辅助细胞克隆扩增对抗核抗体阳性幼年特发性关节炎患者关节B细胞分化的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bba29460969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273421, encodeId=065f12e342184, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=ARD：B细胞耗竭以I型干扰素依赖性方式损害疫苗接种诱导的CD8+ T细胞反应, objectType=article, longId=292826, objectId=692329282612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=692329282612, replyNumber=0, likeNumber=99, createdTime=2021-12-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=692329282612, moduleTitle=ARD：B细胞耗竭以I型干扰素依赖性方式损害疫苗接种诱导的CD8+ T细胞反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=692329282612)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤

2022-07-19

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JNNP:幼稚B细胞和水通道蛋白-4抗体是视神经脊髓炎发病的特征,来自干细胞移植的证据

2022-07-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤

2022-06-24

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤

2022-06-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nature重磅：AAV递送CRISPR，体内改造B细胞，产生广泛中和抗体治疗艾滋病

2022-06-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应

2022-06-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应

2022-06-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究

2022-06-04

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR

2022-05-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关

2022-05-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR

2022-04-28

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批

2022-04-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JCI：北大人民医院申占龙团队揭示亚洲人特异性的IgG1记忆性B细胞抗原受体变异体对结直肠癌微环境中的作用机制

2022-04-10

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效

2022-03-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗

2022-03-24

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？

2022-02-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较

2022-02-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤

2022-02-14

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

A&R：PD-1highCXCR5-CD4+外周T辅助细胞克隆扩增对抗核抗体阳性幼年特发性关节炎患者关节B细胞分化的影响

2022-01-25

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

ARD：B细胞耗竭以I型干扰素依赖性方式损害疫苗接种诱导的CD8+ T细胞反应

2021-12-29

科室
- - 订阅+
  - 更多科室
工具
服务